Aşağıdaki Tabloda , yoğunlaşılmış ilaç geliştirme yaşam döngüsünün farklı aşamalarındaki diğer birçok adayı özetlemektedir. John Cahill
| Company/research | Drug/vaccine candidate | Development stage |
| MIGAL | Infectious Bronchitis Virus (IBV) vaccine | Pre-clinical trials |
| APEIRON Biologics | APN01 | Phase I |
| Tonix Pharmaceuticals | TNX-1800 | Initial evaluation |
| Innovation Pharmaceuticals | Brilacidin | Initial evaluation |
| Clover Biopharmaceuticals | S-Trimer vaccine | Pre-clinical trials |
| Vaxart | TBC | Pre-clinical trials |
| CytoDyn | Leronlimab | Phase II for HIV and fast tracked for COVID-19 |
| Applied DNA Sciences and Takis Biotech | Linear DNA Vaccine | Pre-clinical trials |
| BIOXYTRAN | BX-25 | TBC |
| Novavax | MERS coronavirus vaccine | Phase I in 2020 |
| Biocryst Pharma | Galidesivir | Advanced animal testing |
| Takeda | H-IG therapy | TBC |
| Heat Biologics | gp96 vaccine | Early development |
| Pfizer and BioNTech | mRNA vaccine, BNT162 | Clinical programme development with Fosun in China |
| Generex | Ii-Key immune system activation | Clinical programme development in China |
| Vir Biotechnology/Wuxi Vir Biotechnology/Alnylam | MABs binding to virus siRNA candidates | TBC |
| Janssen Pharmaceuticals | PREZCOBIX® HIV medication (darunavir/cobicistat) | TBC |
As evident above, drug discovery and clinical research activities in COVID-19 prevention and treatment is increasing in pace; it would not be surprising if a workable vaccine has already been discovered and is being tested at present. However, it will take some time to establish the complete safety and efficacy of the successful candidates. Despite this, with the combined knowledge and current urgency that now exists in R&D, we should have reason to be confident of a future without COVID-19. In the meantime, although unfortunately this may still be some months away, we must follow national health authority guidance, trust in science and stay safe for each other.
